AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2422778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for groups I, II, and III)
Number of subjects: 30
Study 2422778 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS administration
Number of subjects: 30
Study 11152033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 0.65-1.0 mg x kg(-1)
Number of subjects: 80
Study 11152033 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 13-20 mg x kg(-1)
Number of subjects: 80
Study 30617465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice shot (BRJ) (6.2 mmol NO3‐)
Number of subjects: 12
Study 30617465 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted placebo (PLA) (<0.004 mmol NO3‐)
Number of subjects: 12
Study 30074112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0
Study 30074112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor combined with aspirin
Number of subjects: 0
Study 30074112 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study 27441380 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cyclists during the Stroop task
Number of subjects: 20
Study 27441380 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational cyclists during the mental exertion condition
Number of subjects: 20
Study 27441380 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cyclists during the mental exertion condition
Number of subjects: 20
Study 27441380 — intervention group
Group type: COMPARATOR
Intervention: Heart rate, blood lactate concentration, and RPE
Number of subjects: 20
Study 25027552 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin (20mg/m2/week) with concurrent radiotherapy (54Gy in 30 fractions)
Number of subjects: 40
Study 25027552 — intervention group
Group type: COMPARATOR
Intervention: docetaxel plus 5-fluorouracil with concurrent radiotherapy
Number of subjects: 40
Study 22551208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal, a non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 130
Study 22551208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20206069 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 704 mg orally twice daily (NAC group, n=15)
Number of subjects: 45
Study 20206069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 250 mg intravenously 30 min before CAG and/or PCI (aminophylline group, n=15)
Number of subjects: 45
Study 20206069 — intervention group
Group type: COMPARATOR
Intervention: Hydration alone (control group, n=15)
Number of subjects: 45
Study 17633369 — intervention group
Group type: EXPERIMENTAL
Intervention: Panlongqi Tablet (PLQ) in addition to NSAID and sulfasalazine (SSZ)
Number of subjects: 104
Study 17633369 — intervention group
Group type: COMPARATOR
Intervention: Control group (NSAID and sulfasalazine only)
Number of subjects: 104
Study 16055815 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment, psychoeducational multi-family groups, social skills training)
Number of subjects: 0
Study 16055815 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 16055815 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 0
Study 12170046 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravenous dexamethasone
Number of subjects: 140
Study 12170046 — intervention group
Group type: COMPARATOR
Intervention: 1 ml intravenous saline (Control)
Number of subjects: 140
Study 10525023 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment based on ductal flow pattern assessment (ECHO group)
Number of subjects: 0
Study 10525023 — intervention group
Group type: COMPARATOR
Intervention: Conventional indomethacin treatment (protocol group)
Number of subjects: 0
Study 9345399 — intervention group
Group type: COMPARATOR
Intervention: 6 and 12 MIU of recombinant human interferon beta (r-hIFN-beta) (Rebif) given subcutaneously three times per week for 24 months in patients with relapsing-remitting MS.
Number of subjects: 0
Study 9345399 — intervention group
Group type: COMPARATOR
Intervention: 6 and 12 MIU of recombinant human interferon beta (r-hIFN-beta) (Rebif) given subcutaneously three times per week for 36 months in patients with secondary progressive MS.
Number of subjects: 0
Study 1689934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg daily
Number of subjects: 37
Study 1689934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 1689934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride 5 mg
Number of subjects: 37
Study 760504 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (80%)
Number of subjects: 6
Study 760504 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (60%)
Number of subjects: 6
Study 760504 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 6
Study 30869971 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist Response Questionnaire (TRQ) responses toward dependent (anaclitic) patients
Number of subjects: 84
Study 30869971 — intervention group
Group type: COMPARATOR
Intervention: Therapist Response Questionnaire (TRQ) responses toward self-critical (introjective) patients
Number of subjects: 84
Study 30869971 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapists' responses
Number of subjects: 84
Study 30869971 — intervention group
Group type: COMPARATOR
Intervention: Initial affective experiences of therapists
Number of subjects: 84
Study 30869971 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' emotional reactions when patients made no therapeutic progress
Number of subjects: 84
Study 28608791 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM
Number of subjects: 600
Study 28608791 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexuals
Number of subjects: 600
Study 26393373 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) prescribed for 15 hours per day including overnight hours
Number of subjects: 114
Study 26393373 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 114
Study 23417588 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative troponin elevation
Number of subjects: 187
Study 23417588 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative troponin level
Number of subjects: 187
Study 23417588 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications
Number of subjects: 187
Study 23417588 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 187
Study 23417588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 187
Study 21636122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg once a day for 4 days)
Number of subjects: 304
Study 21636122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 21636122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 304
Study 19715426 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with plain soap
Number of subjects: 10
Study 19715426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water with plain soap
Number of subjects: 10
Study 19715426 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with antibacterial soap
Number of subjects: 10
Study 19715426 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic hand wipes
Number of subjects: 10
Study 19715426 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol‐based handrub
Number of subjects: 10
Study 17540594 — intervention group
Group type: EXPERIMENTAL
Intervention: hGH (0.05mg/kg/day) for 4 days
Number of subjects: 22
Study 17540594 — intervention group
Group type: COMPARATOR
Intervention: Control group (siblings)
Number of subjects: 22
Study 15513276 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 14
Study 15513276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11450887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime plus netilmicin
Number of subjects: 73
Study 11450887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 73
Study 11450887 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 73
Study 11450887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study 9390662 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g PO b.i.d. x 14 days -> 2 g PO b.i.d. x 7 days)
Number of subjects: 7
Study 7970099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 induction therapy (0.5 mg OKT3 twice daily for 10 days)
Number of subjects: 50
Study 7970099 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone/cyclosporin
Number of subjects: 50
Study 7970099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 induction therapy
Number of subjects: 50
Study 2885650 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus pulsed ultrasound given weekly
Number of subjects: 108
Study 2885650 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (paste impregnated bandage and a self‐adhesive elastic bandage)
Number of subjects: 108
Study 31748223 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 weeks
Number of subjects: 2760
Study 31748223 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 2760
Study 28592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace element measurements (vanadium and chromium)
Number of subjects: 36
Study 28592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC) estimated glomerular filtration rate (eGFR)
Number of subjects: 36
Study 28592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental exposure to chromium and vanadium
Number of subjects: 36
Study 25725487 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific inhibition (inhibition in response to unhealthy food stimuli only)
Number of subjects: 72
Study 25725487 — intervention group
Group type: EXPERIMENTAL
Intervention: General inhibition (inhibition not contingent on type of stimuli)
Number of subjects: 72
Study 25725487 — intervention group
Group type: COMPARATOR
Intervention: Control (no inhibition)
Number of subjects: 72
Study 23756959 — intervention group
Group type: EXPERIMENTAL
Intervention: New connecting tube protocol
Number of subjects: 80
Study 23756959 — intervention group
Group type: COMPARATOR
Intervention: Conventional tube protocol
Number of subjects: 80
Study 21303311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) at a dose of 200 mcg once daily for eight weeks after RF application
Number of subjects: 50
Study 21303311 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency application
Number of subjects: 50
Study 19996505 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical parameters including total cholesterol, LDL cholesterol, Apo‐B, Lp(a), triglycerides, hs‐C‐reactive protein (CRP), interleukines (IL‐1beta and IL‐6), fibrinogen, D‐dimers
Number of subjects: 0
Study 19996505 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol, Apo‐A‐1, protein C
Number of subjects: 0
Study 16352683 — intervention group
Group type: EXPERIMENTAL
Intervention: CJC-1295
Number of subjects: 0
Study 16352683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15193471 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 40
Study 15193471 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl CR, Ferring) every 6 weeks
Number of subjects: 40
Study 10678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A in capsules (4 capsules of Hup, each contains 50 micrograms)
Number of subjects: 60
Study 10678137 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine-A in tablets (4 tablets of Hup, each contains 50 micrograms)
Number of subjects: 60
Study 10678137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 tablets of placebo in capsule group and 4 capsules of placebo in tablet group)
Number of subjects: 60
Study 9289430 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogs
Number of subjects: 33
Study 9289430 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutics PAC and radiotherapy
Number of subjects: 33
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg pyridoxine (PN)-HCl/d supplementation for mothers
Number of subjects: 0
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 mg pyridoxine (PN)-HCl/d supplementation for mothers
Number of subjects: 0
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PN-HCl/d supplementation for infants of 2 mg/d supplemented mothers
Number of subjects: 0
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B-6 intake
Number of subjects: 0
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma pyridoxal-5'-phosphate (PLP) concentrations
Number of subjects: 0
Study 1503068 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase activity in mother's milk and infant plasma
Number of subjects: 0
Study 6299652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 127
Study 6299652 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 250 mg daily
Number of subjects: 127
Study 31393072 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 123
Study 31393072 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Number of subjects: 123
Study 27869481 — intervention group
Group type: EXPERIMENTAL
Intervention: Papillary approach (Group 1)
Number of subjects: 55
Study 27869481 — intervention group
Group type: COMPARATOR
Intervention: Infundibular approach (Group 2)
Number of subjects: 55
Study 25634934 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of information about nicotine and toxicity in smokeless tobacco products
Number of subjects: 0
Study 25634934 — intervention group
Group type: COMPARATOR
Intervention: Presentation of toxicity information alone
Number of subjects: 0
Study 25634934 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of information about SLT and cigarette products
Number of subjects: 0
Study 25634934 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall presentation of tobacco constituent information
Number of subjects: 0
Study 23866179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg)
Number of subjects: 2616
Study 23866179 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg, 75 mg for pre-treated patients)
Number of subjects: 2616
Study 21428727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 or 50 mg, depending on renal function)
Number of subjects: 206
Study 21428727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 21428727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 206
Study 19216813 — intervention group
Group type: EXPERIMENTAL
Intervention: Large food portions
Number of subjects: 43
Study 19216813 — intervention group
Group type: COMPARATOR
Intervention: Standard food portions
Number of subjects: 43
Study 17910226 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforce (E)
Number of subjects: 40
Study 17910226 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC (RX)
Number of subjects: 40
Study 17910226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fill Magic Dual Cement (FM)
Number of subjects: 40
Study 17910226 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth (Control)
Number of subjects: 40
Study 15492353 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.01-0.06 mg/kg/day, mean dosage: 0.04 mg/kg/day)
Number of subjects: 79
Study 15492353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 15492353 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 79
Study 12088139 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention including parent training, social behavior interventions, and supplementary reading instruction over a 2-year period
Number of subjects: 284
Study 12088139 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 284
Study 10094445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg/kg per 6 h for 4 days)
Number of subjects: 52
Study 10094445 — intervention group
Group type: COMPARATOR
Intervention: Control (antibiotics alone)
Number of subjects: 52
Study 10094445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 52
Study 10094445 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 8625186 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 71
Study 8625186 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus LAK
Number of subjects: 71
Study 2187651 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol-240
Number of subjects: 50
Study 2187651 — intervention group
Group type: COMPARATOR
Intervention: iohexol-240 (Omnipaque-240)
Number of subjects: 50
Study 6996137 — intervention group
Group type: EXPERIMENTAL
Intervention: Tienilic acid
Number of subjects: 23
Study 6996137 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 23
Study 6548926 — intervention group
Group type: EXPERIMENTAL
Intervention: Almax (6-8 g/d)
Number of subjects: 169
Study 6548926 — intervention group
Group type: COMPARATOR
Intervention: Almax (4 g/d) with antisecretory drugs (cimetidine or ranitidine)
Number of subjects: 169
Study 6548926 — intervention group
Group type: EXPERIMENTAL
Intervention: Almax (lower doses)
Number of subjects: 169
Study 6548926 — intervention group
Group type: EXPERIMENTAL
Intervention: Almax (all groups)
Number of subjects: 169
Study 31679170 — intervention group
Group type: EXPERIMENTAL
Intervention: Presession Attention (PA)
Number of subjects: 6
Study 31679170 — intervention group
Group type: COMPARATOR
Intervention: No Presession Attention (NPA)
Number of subjects: 6
Study 30005707 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture group receiving standardized 30-min real acupuncture treatment for a total of 16 sessions on top of standard routine care.
Number of subjects: 100
Study 30005707 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group receiving sham acupuncture in addition to standard routine care.
Number of subjects: 100
Study 30005707 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture group
Number of subjects: 100
Study 30005707 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture group
Number of subjects: 100
Study 27374465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy (375 mg/m² every 3 months for 2 years)
Number of subjects: 263
Study 27374465 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 263
Study 27374465 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 263
Study 23708056 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (9 g daily for 6 months)
Number of subjects: 88
Study 22748516 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 184
Study 22748516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 20493971 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlobe blood gases
Number of subjects: 10
Study 20493971 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlobe pulse oximetry O(2) saturation (Sp(O2))
Number of subjects: 10
Study 20493971 — intervention group
Group type: COMPARATOR
Intervention: Arterial blood gases
Number of subjects: 10
Study 18371137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FeCarb) - maximum 1,000 mg iron per infusion at 1-week intervals until total iron deficit reached
Number of subjects: 200
Study 18371137 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FeSulf) - 100 mg b.i.d. for 12 weeks
Number of subjects: 200
Study 15855366 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-cruciate-ligament-substituting total knee arthroplasty
Number of subjects: 44
Study 15855366 — intervention group
Group type: COMPARATOR
Intervention: Posterior-cruciate-ligament-retaining total knee arthroplasty
Number of subjects: 44
Study 15855366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both designs
Number of subjects: 44
Study 12621634 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Dystonia Rating Scale (UDRS)
Number of subjects: 100
Study 12621634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fahn‐Marsden Scale (F‐M)
Number of subjects: 100
Study 12621634 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Dystonia Rating Scale (GDS)
Number of subjects: 100
Study 12621634 — intervention group
Group type: COMPARATOR
Intervention: Comparison among scales (UDRS, F‐M, GDS)
Number of subjects: 100
Study 10584678 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch containing 35 mg nicotine
Number of subjects: 16
Study 10584678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8631044 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (8 patients)
Number of subjects: 12
Study 1826594 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin at 6 mg/kg every 12 h for three doses, then 6 mg/kg every 24 h
Number of subjects: 54
Study 1826594 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin at 15 mg/kg every 12 h
Number of subjects: 54
Study 6961760 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (667 mg daily)
Number of subjects: 18
Study 6961760 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (129 mg daily)
Number of subjects: 18
Study 6961760 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg single oral dose)
Number of subjects: 18
Study 30895881 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored family-based self-management education and social support intervention (group education, home visits, telephone calls)
Number of subjects: 157